VolitionRx Limited (NYSE American: VNRX) has announced the release of a clinical study demonstrating the prognostic value of its Nu.Q Cancer Assay in patients newly diagnosed with lung cancer. Conducted in collaboration with researchers and clinicians at France’s Hospices Civils de Lyon, the real-world study found that levels of the assay’s H3K27Me3-nucleosome biomarker were associated with cancer stage, overall survival and progression-free survival.
The findings, currently under peer review, indicate that a prognostic model incorporating the biomarker and clinical factors successfully stratified patients into low- and high-risk mortality groups. Volition said the results support the potential use of Nu.Q Cancer to help personalize treatment selection and improve clinical decision-making.
Volition also announced that clinical certification of the test at Hospices Civils de Lyon has been completed, and the company is preparing a reimbursement submission in France under the RIHN framework. Reimbursement represents a key milestone toward routine clinical use in France, and Volition is pursuing commercialization opportunities with hospital networks and potential licensing partners internationally.
The study’s implications are significant for lung cancer management, where prognosis and treatment response vary widely among patients. If validated and adopted, the Nu.Q Cancer Assay could provide clinicians with a non-invasive tool to better predict outcomes and tailor therapies, potentially improving survival rates and quality of life.
For more details, the full press release is available at https://ibn.fm/dhJZ6. Volition is a multinational company focused on advancing epigenetics, developing simple, cost-effective blood tests for early detection and monitoring of diseases including cancer and sepsis. Its research and development activities are centered in Belgium, with offices in the U.S. and London. Further information can be found on the company’s website at https://volition.com/.
This news matters because it moves the Nu.Q Cancer Assay closer to clinical adoption, potentially offering a new tool for managing lung cancer—a leading cause of cancer death worldwide. The ability to stratify patients by risk could enable more aggressive treatment for high-risk patients while sparing low-risk patients from unnecessary side effects, improving overall care.
This news story relied on content distributed by InvestorBrandNetwork (IBN). Blockchain Registration, Verification & Enhancement provided by NewsRamp™. The source URL for this press release is VolitionRx Nu.Q Cancer Assay Shows Prognostic Value in Lung Cancer Study.